{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:16:29Z","timestamp":1788362189147,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004147","name":"Tsinghua University","doi-asserted-by":"publisher","award":["52302102323"],"award-info":[{"award-number":["52302102323"]}],"id":[{"id":"10.13039\/501100004147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011620","name":"Center for Life Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350108"],"award-info":[{"award-number":["82350108"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["T2495270"],"award-info":[{"award-number":["T2495270"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["hLife"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.hlife.2026.05.003","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:38:40Z","timestamp":1779320320000},"page":"423-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted protein degradation via chimeric antigen receptor (CAR)-mediated antigen endocytosis in T cells"],"prefix":"10.1016","volume":"4","author":[{"given":"Youguang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-0660","authenticated-orcid":false,"given":"Min","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlife.2026.05.003_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hlife.2026.05.003_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled Phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.hlife.2026.05.003_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hlife.2026.05.003_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/12034754231188444","article-title":"A systematic review and meta-analysis of injection site reactions in randomized-controlled trials of biologic injections","volume":"27","author":"Kim","year":"2023","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.hlife.2026.05.003_bib5","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/1078-0432.CCR-21-0168","article-title":"Antidrug antibodies and drug development: Challenges in the immunotherapy era","volume":"27","author":"de Sp\u00e9ville","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hlife.2026.05.003_bib6","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlife.2026.05.003_bib7","article-title":"Effect of anti-tnf antibodies on clinical response in rheumatoid arthritis patients: A meta-analysis","volume":"2016","author":"Wu","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.hlife.2026.05.003_bib8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hlife.2026.05.003_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.05.003_bib10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.hlife.2026.05.003_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","article-title":"Antibody targeting of E3 ubiquitin ligases for receptor degradation","volume":"610","author":"Marei","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.05.003_bib12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","article-title":"Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins","volume":"41","author":"Pance","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.hlife.2026.05.003_bib13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.chembiol.2023.05.010","article-title":"ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation","volume":"30","author":"Sun","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.hlife.2026.05.003_bib14","article-title":"Development of a bispecific DNA-aptamer-based lysosome-targeting chimera for HER2 protein degradation","volume":"4","author":"Hamada","year":"2023","journal-title":"Cell Re Phys Sci"},{"key":"10.1016\/j.hlife.2026.05.003_bib15","doi-asserted-by":"crossref","first-page":"16377","DOI":"10.1021\/jacs.1c08521","article-title":"Covalently engineered nanobody chimeras for targeted membrane protein degradation","volume":"143","author":"Zhang","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.hlife.2026.05.003_bib16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41589-021-00851-1","article-title":"Bifunctional small molecules that mediate the degradation of extracellular proteins","volume":"17","author":"Caianiello","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.hlife.2026.05.003_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hlife.2026.05.003_bib18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: Expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hlife.2026.05.003_bib19","doi-asserted-by":"crossref","first-page":"24272","DOI":"10.1021\/jacs.3c08886","article-title":"Insulin-like growth factor 2 (IGF2)-fused lysosomal targeting chimeras for degradation of extracellular and membrane proteins","volume":"145","author":"Zhang","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.hlife.2026.05.003_bib20","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.3390\/molecules28227519","article-title":"IGF2 peptide-based LYTACs for targeted degradation of extracellular and transmembrane proteins","volume":"28","author":"Mikitiuk","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.hlife.2026.05.003_bib21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1006\/dbio.1996.0182","article-title":"Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds","volume":"177","author":"Ludwig","year":"1996","journal-title":"Dev Biol"},{"key":"10.1016\/j.hlife.2026.05.003_bib22","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.chembiol.2024.01.002","article-title":"Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor","volume":"31","author":"Su","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.hlife.2026.05.003_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nature11019","article-title":"ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner","volume":"485","author":"Hao","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.05.003_bib24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nature11308","article-title":"Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors","volume":"488","author":"Koo","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.05.003_bib25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1101\/gad.235473.113","article-title":"The R-spondin\/Lgr5\/Rnf43 module: Regulator of Wnt signal strength","volume":"28","author":"de Lau","year":"2014","journal-title":"Genes Dev"},{"key":"10.1016\/j.hlife.2026.05.003_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1152\/physrev.1987.67.2.520","article-title":"The physiology of transferrin and transferrin receptors","volume":"67","author":"Huebers","year":"1987","journal-title":"Physiol Rev"},{"key":"10.1016\/j.hlife.2026.05.003_bib27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlife.2026.05.003_bib28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlife.2026.05.003_bib29","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1345\/aph.1G256","article-title":"Thalidomide-associated thrombocytopenia","volume":"39","author":"Duyvendak","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.hlife.2026.05.003_bib30","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1200\/JCO.2006.06.5920","article-title":"Encephalopathy in a patient after long-term treatment with thalidomide","volume":"24","author":"Sohlbach","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hlife.2026.05.003_bib31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4065\/82.5.638","article-title":"Thalidomide-induced fulminant hepatic failure","volume":"82","author":"Hamadani","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.hlife.2026.05.003_bib32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","article-title":"Engineered cellular immunotherapies in cancer and beyond","volume":"28","author":"Finck","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.hlife.2026.05.003_bib33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.abq6990","article-title":"The future of engineered immune cell therapies","volume":"378","author":"Irvine","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.hlife.2026.05.003_bib34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: Design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.05.003_bib35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.05.003_bib36","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.hlife.2024.05.005","article-title":"BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy","volume":"2","author":"Zhang","year":"2024","journal-title":"hLife"},{"key":"10.1016\/j.hlife.2026.05.003_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hlife.2025.02.003","article-title":"Harnessing allogeneic CAR-T cell therapy for autoimmune conditions","volume":"3","author":"Yan","year":"2025","journal-title":"hLife"},{"key":"10.1016\/j.hlife.2026.05.003_bib39","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.immuni.2020.07.011","article-title":"Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy","volume":"53","author":"Li","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.hlife.2026.05.003_bib38","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1073\/pnas.88.7.2830","article-title":"Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific","volume":"88","author":"Lewis","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hlife.2026.05.003_bib40","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/j.hlife.2026.05.003_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00281-003-0125-3","article-title":"The TNF-\u03b1 transgenic mouse model of inflammatory arthritis","volume":"25","author":"Li","year":"2003","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.hlife.2026.05.003_bib42","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.hlife.2026.05.003_bib43","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.ymthe.2021.02.024","article-title":"Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity","volume":"29","author":"Murad","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlife.2026.05.003_bib44","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20232368","article-title":"Induction of immortal-like and functional CAR T cells by defined factors","volume":"221","author":"Wang","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.hlife.2026.05.003_bib45","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41590-024-01834-9","article-title":"A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice","volume":"25","author":"Jin","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.hlife.2026.05.003_bib46","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.hlife.2026.05.003_bib47","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.hlife.2026.05.003_bib48","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hlife.2026.05.003_bib49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nchembio.2565","article-title":"Rewiring T-cell responses to soluble factors with chimeric antigen receptors","volume":"14","author":"Chang","year":"2018","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.hlife.2026.05.003_bib50","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.hlife.2024.06.002","article-title":"Boosting CAR-T cell therapy with CRISPR technology","volume":"2","author":"Yan","year":"2024","journal-title":"hLife"},{"key":"10.1016\/j.hlife.2026.05.003_bib51","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8+ T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.hlife.2026.05.003_bib52","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.hlife.2026.05.003_bib53","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy\u2014How far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.hlife.2026.05.003_bib54","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: Harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hlife.2026.05.003_bib55","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.hlife.2026.05.003_bib56","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlife.2026.05.003_bib57","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: The Phase 1\/2 CASTLE basket trial","volume":"32","author":"Muller","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.hlife.2026.05.003_bib58","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.hlife.2026.05.003_bib59","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard-2024-226437","article-title":"CD-19 CAR-T cells for polyrefractory rheumatoid arthritis","volume":"84","author":"Lidar","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.hlife.2026.05.003_bib60","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hlife.2026.05.003_bib61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nature02238","article-title":"T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases","volume":"427","author":"Mempel","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.hlife.2026.05.003_bib62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/B978-0-12-418687-3.00018-5","article-title":"Transient mammalian cell transfection with polyethylenimine (PEI)","volume":"529","author":"Longo","year":"2013","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.hlife.2026.05.003_bib63","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2004.08.017","article-title":"Compartmentalization of TNF receptor 1 signaling: Internalized TNF receptosomes as death signaling vesicles","volume":"21","author":"Schneider-Brachert","year":"2004","journal-title":"Immunity"}],"container-title":["hLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949928326000313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949928326000313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:43:59Z","timestamp":1788360239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949928326000313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2949928326000313"],"URL":"https:\/\/doi.org\/10.1016\/j.hlife.2026.05.003","relation":{},"ISSN":["2949-9283"],"issn-type":[{"value":"2949-9283","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted protein degradation via chimeric antigen receptor (CAR)-mediated antigen endocytosis in T cells","name":"articletitle","label":"Article Title"},{"value":"hLife","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlife.2026.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Institute of Microbiology, Chinese Academy of Sciences.","name":"copyright","label":"Copyright"}]}}